Rainer Boehm

Interim Division Head & Chief Executive Officer, Novartis Pharmaceuticals at Novartis AG

Rainer Boehm

Rainer Boehm

Interim Division Head & Chief Executive Officer, Novartis Pharmaceuticals at Novartis AG

Overview
RelSci Relationships

1342

Number of Boards

3

Birthday

1961

Age

58

Relationships
RelSci Relationships are individuals Rainer Boehm likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer, Novartis Oncology at Novartis AG

Relationship likelihood: Strong

Founder at Cellectis SA

Relationship likelihood: Strong

Co-Founder at Cellectis SA

Relationship likelihood: Strong

Chief Executive Officer at Novartis AG

Relationship likelihood: Strong

Chief Financial Officer at Novartis AG

Relationship likelihood: Strong

Chief Executive Officer & Director at Alcon, Inc.

Relationship likelihood: Strong

Executive Partner at Mpm Capital LLC

Relationship likelihood: Strong

Chief People & Organization Officer at Novartis AG

Relationship likelihood: Strong

Chief Digital Officer at Novartis AG

Relationship likelihood: Strong

Scientific Founder at C4 Therapeutics, Inc.

Relationship likelihood: Strong

Paths to Rainer Boehm
Potential Connections via
Relationship Science
You
Rainer Boehm
Interim Division Head & Chief Executive Officer, Novartis Pharmaceuticals at Novartis AG
Education

Ulm University (German: Universität Ulm) is a public university in the city of Ulm, in the South German state of Baden-Württemberg. The university was founded in 1967 and focuses on natural sciences, medicine, engineering sciences, mathematics, economics and computer science. With 9,188 students (summer semester 2013), it is one of the youngest public universities in Germany. Times Higher Education (THE) ranks it at position 16 among the world's top 100 universities under the age of 50 years in 2014, making it the highest-ranked young university in Germany.

Career History
Interim Division Head & Chief Executive Officer, Novartis Pharmaceuticals
Current

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Chief Commercial & Medical Affairs Officer
Current

Novartis Pharma AG develops and manufactures pharmaceuticals. It is a subsidiary of Novartis AG. The company is headquartered in Basel, Germany.

Interim Head
Prior - 2016

Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.

Boards & Committees
Independent Director
2018 - Current

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway.

Independent Director
2018 - Current

Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the developing next-generation cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor (\"GM-CSF\") neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.

Director
2017 - Current

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Rainer Boehm. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Rainer Boehm's profile does not indicate a business or promotional relationship of any kind between RelSci and Rainer Boehm.